RANI Stock Overview
Operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rani Therapeutics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.50 |
| 52 Week High | US$8.75 |
| 52 Week Low | US$1.82 |
| Beta | 0.34 |
| 1 Month Change | -23.08% |
| 3 Month Change | 46.67% |
| 1 Year Change | 18.79% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -50.00% |
Recent News & Updates
Shareholder Returns
| RANI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 23.9% | 0.02% | -0.6% |
| 1Y | 18.8% | 15.8% | 22.2% |
Return vs Industry: RANI exceeded the US Pharmaceuticals industry which returned 15.8% over the past year.
Return vs Market: RANI underperformed the US Market which returned 22.2% over the past year.
Price Volatility
| RANI volatility | |
|---|---|
| RANI Average Weekly Movement | 16.6% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: RANI's share price has been volatile over the past 3 months.
Volatility Over Time: RANI's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 140 | Talat Imran | www.ranitherapeutics.com |
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions.
Rani Therapeutics Holdings, Inc. Fundamentals Summary
| RANI fundamental statistics | |
|---|---|
| Market cap | US$277.31m |
| Earnings (TTM) | -US$33.08m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.4x
P/E RatioIs RANI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RANI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$33.08m |
| Earnings | -US$33.08m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.26 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 202.5% |
How did RANI perform over the long term?
See historical performance and comparison